Piotr M.
- Country
- Poland
- Department
- Oddzial Radioterapii
Research Overview
- Phase 3 Randomized, Double-blind, Placebo-controlled Study of Apalutamide and GnRH Agonist in High-risk Localized or Locally Advanced Prostate Cancer with Primary Radiation Therapy
- Evaluation of Apalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Data & Insights
Has run more than one trial at 5 of 104 partner sites.
Specializations
Prostate Cancer Research
This investigator specializes in advanced therapeutic approaches for prostate cancer, with particular emphasis on treating complex cases that have become resistant to conventional treatments.
- Castration-Resistant Prostate Cancer (CRPC)
- High-risk Localized Prostate Cancer
- Locally Advanced Prostate Cancer
The investigator's work encompasses innovative treatment strategies for patients with varying stages of prostate cancer progression.
Treatment Innovation
The investigator focuses on evaluating novel therapeutic agents, particularly apalutamide (ARN-509), in combination with established treatment modalities.
- Primary Radiation Therapy Integration
- GnRH Agonist Combination Therapy
- Metastasis-Free Survival Assessment
Their research explores the effectiveness of combined treatment approaches in managing advanced prostate cancer.
Diagnostic Approaches
The investigator employs advanced diagnostic methodologies to evaluate treatment outcomes in prostate cancer patients.
- Conventional Imaging Techniques
- PSMA-PET Imaging
- Biomarker Assessment
Their work incorporates state-of-the-art imaging technologies for precise disease monitoring and treatment response evaluation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.